Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, believes that the CDMOs such as ours can improve global access to medications by developing cost-effective, optimized production processes.
Natalia adds that VIVEbiotech, a CDMO specializing in lentiviral vectors for cell and gene therapy, focuses on innovation in automation, continuous monitoring, and scalable manufacturing, reinforcing how all these points lower production costs, making advanced therapies more affordable and accessible. She believes this could increase treatment availability, especially in less-developed countries, and support sustainable healthcare solutions.
You can read the very interesting full piece in which, in addition to Natalia’s, the opinions of several other experts in the field are reflected here: https://www.pharmasalmanac.com/articles/how-can-biopharmaceutical-companies-contribute-to-improving-global-access-to-essential-medications